As of today, anti-PD1 (e.g., pembrolizumab, nivolumab) and anti-PD-L1 (e.g., atezolizumab, durvalumab) monoclonal antibodies (mAb) have become some of the most widely prescribed anticancer therapies and are recommended, in monotherapy or combination with other ICI or chemotherapy (CT), in a broad spectrum of cancer types [1]. Here, CD274 is linked to cancer.